304 related articles for article (PubMed ID: 12534345)
1. Physical interaction of tumour suppressor p53/p73 with CCAAT-binding transcription factor 2 (CTF2) and differential regulation of human high-mobility group 1 (HMG1) gene expression.
Uramoto H; Izumi H; Nagatani G; Ohmori H; Nagasue N; Ise T; Yoshida T; Yasumoto K; Kohno K
Biochem J; 2003 Apr; 371(Pt 2):301-10. PubMed ID: 12534345
[TBL] [Abstract][Full Text] [Related]
2. p73 independent of c-Myc represses transcription of platelet-derived growth factor beta-receptor through interaction with NF-Y.
Hackzell A; Uramoto H; Izumi H; Kohno K; Funa K
J Biol Chem; 2002 Oct; 277(42):39769-76. PubMed ID: 12167641
[TBL] [Abstract][Full Text] [Related]
3. HMGB1 and HMGB2 cell-specifically down-regulate the p53- and p73-dependent sequence-specific transactivation from the human Bax gene promoter.
Stros M; Ozaki T; Bacikova A; Kageyama H; Nakagawara A
J Biol Chem; 2002 Mar; 277(9):7157-64. PubMed ID: 11748232
[TBL] [Abstract][Full Text] [Related]
4. Deletion of the COOH-terminal region of p73alpha enhances both its transactivation function and DNA-binding activity but inhibits induction of apoptosis in mammalian cells.
Ozaki T; Naka M; Takada N; Tada M; Sakiyama S; Nakagawara A
Cancer Res; 1999 Dec; 59(23):5902-7. PubMed ID: 10606232
[TBL] [Abstract][Full Text] [Related]
5. Two new p73 splice variants, gamma and delta, with different transcriptional activity.
De Laurenzi V; Costanzo A; Barcaroli D; Terrinoni A; Falco M; Annicchiarico-Petruzzelli M; Levrero M; Melino G
J Exp Med; 1998 Nov; 188(9):1763-8. PubMed ID: 9802988
[TBL] [Abstract][Full Text] [Related]
6. p73 competes with p53 and attenuates its response in a human ovarian cancer cell line.
Vikhanskaya F; D'Incalci M; Broggini M
Nucleic Acids Res; 2000 Jan; 28(2):513-9. PubMed ID: 10606650
[TBL] [Abstract][Full Text] [Related]
7. p73 competes with co-activators and recruits histone deacetylase to NF-Y in the repression of PDGF beta-receptor.
Uramoto H; Wetterskog D; Hackzell A; Matsumoto Y; Funa K
J Cell Sci; 2004 Oct; 117(Pt 22):5323-31. PubMed ID: 15454570
[TBL] [Abstract][Full Text] [Related]
8. Identification of direct p73 target genes combining DNA microarray and chromatin immunoprecipitation analyses.
Fontemaggi G; Kela I; Amariglio N; Rechavi G; Krishnamurthy J; Strano S; Sacchi A; Givol D; Blandino G
J Biol Chem; 2002 Nov; 277(45):43359-68. PubMed ID: 12213815
[TBL] [Abstract][Full Text] [Related]
9. Regulation of the p53 homolog p73 by adenoviral oncogene E1A.
Das S; El-Deiry WS; Somasundaram K
J Biol Chem; 2003 May; 278(20):18313-20. PubMed ID: 12639967
[TBL] [Abstract][Full Text] [Related]
10. Functional inactivation of p73, a homolog of p53 tumor suppressor protein, by human papillomavirus E6 proteins.
Park JS; Kim EJ; Lee JY; Sin HS; Namkoong SE; Um SJ
Int J Cancer; 2001 Mar; 91(6):822-7. PubMed ID: 11275986
[TBL] [Abstract][Full Text] [Related]
11. Kinase activity-independent suppression of p73alpha by AMP-activated kinase alpha (AMPKalpha).
Lee YG; Lee SW; Sin HS; Kim EJ; Um SJ
Oncogene; 2009 Feb; 28(7):1040-52. PubMed ID: 19079340
[TBL] [Abstract][Full Text] [Related]
12. Identification of Daxx interacting with p73, one of the p53 family, and its regulation of p53 activity by competitive interaction with PML.
Kim EJ; Park JS; Um SJ
Nucleic Acids Res; 2003 Sep; 31(18):5356-67. PubMed ID: 12954772
[TBL] [Abstract][Full Text] [Related]
13. Transactivation-deficient p73alpha (p73Deltaexon2) inhibits apoptosis and competes with p53.
Fillippovich I; Sorokina N; Gatei M; Haupt Y; Hobson K; Moallem E; Spring K; Mould M; McGuckin MA; Lavin MF; Khanna KK
Oncogene; 2001 Jan; 20(4):514-22. PubMed ID: 11313982
[TBL] [Abstract][Full Text] [Related]
14. p73 Interacts with c-Myc to regulate Y-box-binding protein-1 expression.
Uramoto H; Izumi H; Ise T; Tada M; Uchiumi T; Kuwano M; Yasumoto K; Funa K; Kohno K
J Biol Chem; 2002 Aug; 277(35):31694-702. PubMed ID: 12080043
[TBL] [Abstract][Full Text] [Related]
15. p73 function is inhibited by tumor-derived p53 mutants in mammalian cells.
Di Como CJ; Gaiddon C; Prives C
Mol Cell Biol; 1999 Feb; 19(2):1438-49. PubMed ID: 9891077
[TBL] [Abstract][Full Text] [Related]
16. New p73 variants with altered C-terminal structures have varied transcriptional activities.
Ueda Y; Hijikata M; Takagi S; Chiba T; Shimotohno K
Oncogene; 1999 Sep; 18(35):4993-8. PubMed ID: 10490834
[TBL] [Abstract][Full Text] [Related]
17. p21/CDKN1A mediates negative regulation of transcription by p53.
Löhr K; Möritz C; Contente A; Dobbelstein M
J Biol Chem; 2003 Aug; 278(35):32507-16. PubMed ID: 12748190
[TBL] [Abstract][Full Text] [Related]
18. Expression of cyclin-dependent kinase subunit 1 (Cks1) is regulated during the cell cycle by a CDE/CHR tandem element and is downregulated by p53 but not by p63 or p73.
Rother K; Li YY; Tschöp K; Kirschner R; Müller GA; Mössner J; Engeland K
Cell Cycle; 2007 Apr; 6(7):853-62. PubMed ID: 17377499
[TBL] [Abstract][Full Text] [Related]
19. Function of p73, not of p53, is inhibited by the physical interaction with RACK1 and its inhibitory effect is counteracted by pRB.
Ozaki T; Watanabe K; Nakagawa T; Miyazaki K; Takahashi M; Nakagawara A
Oncogene; 2003 May; 22(21):3231-42. PubMed ID: 12761493
[TBL] [Abstract][Full Text] [Related]
20. Wild-type p53 and p73 negatively regulate expression of proliferation related genes.
Scian MJ; Carchman EH; Mohanraj L; Stagliano KE; Anderson MA; Deb D; Crane BM; Kiyono T; Windle B; Deb SP; Deb S
Oncogene; 2008 Apr; 27(18):2583-93. PubMed ID: 17982488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
